Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Amer M. Zeidan; Prajwal C. Boddu; Mrinal M. Patnaik; Jan Philipp Bewersdorf; Maximilian Stahl; Raajit K. Rampal; Rory Shallis; David P. Steensma; Michael R. Savona; Mikkael A. Sekeres; Gail J. Roboz; Daniel J. DeAngelo; Andre C. Schuh; Eric Padron; Joshua F. Zeidner; Roland B. Walter; Francesco Onida; Amir Fathi; Amy DeZern; Gabriela Hobbs; Eytan M. Stein; Paresh Vyas; Andrew H. Wei; David T. Bowen; Pau Montesinos; Elizabeth A. Griffiths; Amit K. Verma; Alla Keyzner; Michal Bar-Natan; Shyamala C. Navada; Marina Kremyanskaya; Aaron D. Goldberg; Aref Al-Kali; Mark L. Heaney; Aziz Nazha; Huda Salman; Selina Luger; Keith W. Pratz; Heiko Konig; Rami Komrokji; Michael Deininger; Blanca Xicoy Cirici; Vijaya Raj Bhatt; Lewis R. Silverman; Harry P. Erba; Pierre Fenaux; Uwe Platzbecker; Valeria Santini; Eunice S. Wang; Martin S. Tallman; Richard M. Stone; John Mascarenhas

doi:10.1016/S2352-3026(20)30205-2

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Amer M. Zeidan^*, Prajwal C. Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal, Rory Shallis, David P. Steensma, Michael R. Savona, Mikkael A. Sekeres, Gail J. Roboz, Daniel J. DeAngelo, Andre C. Schuh, Eric Padron, Joshua F. Zeidner, Roland B. Walter, Francesco Onida, Amir Fathi, Amy DeZern, Gabriela HobbsEytan M. Stein, Paresh Vyas, Andrew H. Wei, David T. Bowen, Pau Montesinos, Elizabeth A. Griffiths, Amit K. Verma, Alla Keyzner, Michal Bar-Natan, Shyamala C. Navada, Marina Kremyanskaya, Aaron D. Goldberg, Aref Al-Kali, Mark L. Heaney, Aziz Nazha, Huda Salman, Selina Luger, Keith W. Pratz, Heiko Konig, Rami Komrokji, Michael Deininger, Blanca Xicoy Cirici, Vijaya Raj Bhatt, Lewis R. Silverman, Harry P. Erba, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Eunice S. Wang, Martin S. Tallman, Richard M. Stone, John Mascarenhas

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

54 Scopus citations

Abstract

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.

Original language	English (US)
Pages (from-to)	e601-e612
Journal	The Lancet Haematology
Volume	7
Issue number	8
DOIs	https://doi.org/10.1016/S2352-3026(20)30205-2
State	Published - Aug 2020

Funding

The experts on this panel are haematologists and oncologists who specialise in leukaemia and transplant care, and discussions were held through virtual, online meetings. No external support was received for this Viewpoint. Amer M Zeidan is a Leukaemia and Lymphoma Society scholar in clinical research and is also supported by a National Cancer Institute's Cancer Clinical Investigator Team Leadership Award. Research reported in this publication was in part financially supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA016359. The content of this Viewpoint is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. This publication was not funded by the National Institutes of Health. The funder of the publication had no role in the writing of the report. The corresponding author had final responsibility for the decision to submit for publication.

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2352-3026(20)30205-2

Cite this

Zeidan, A. M., Boddu, P. C., Patnaik, M. M., Bewersdorf, J. P., Stahl, M., Rampal, R. K., Shallis, R., Steensma, D. P., Savona, M. R., Sekeres, M. A., Roboz, G. J., DeAngelo, D. J., Schuh, A. C., Padron, E., Zeidner, J. F., Walter, R. B., Onida, F., Fathi, A., DeZern, A., ... Mascarenhas, J. (2020). Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. The Lancet Haematology, 7(8), e601-e612. https://doi.org/10.1016/S2352-3026(20)30205-2

@article{3bdd2d24f8754166be28453e90a99b24,

title = "Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts",

abstract = "The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.",

author = "Zeidan, {Amer M.} and Boddu, {Prajwal C.} and Patnaik, {Mrinal M.} and Bewersdorf, {Jan Philipp} and Maximilian Stahl and Rampal, {Raajit K.} and Rory Shallis and Steensma, {David P.} and Savona, {Michael R.} and Sekeres, {Mikkael A.} and Roboz, {Gail J.} and DeAngelo, {Daniel J.} and Schuh, {Andre C.} and Eric Padron and Zeidner, {Joshua F.} and Walter, {Roland B.} and Francesco Onida and Amir Fathi and Amy DeZern and Gabriela Hobbs and Stein, {Eytan M.} and Paresh Vyas and Wei, {Andrew H.} and Bowen, {David T.} and Pau Montesinos and Griffiths, {Elizabeth A.} and Verma, {Amit K.} and Alla Keyzner and Michal Bar-Natan and Navada, {Shyamala C.} and Marina Kremyanskaya and Goldberg, {Aaron D.} and Aref Al-Kali and Heaney, {Mark L.} and Aziz Nazha and Huda Salman and Selina Luger and Pratz, {Keith W.} and Heiko Konig and Rami Komrokji and Michael Deininger and Cirici, {Blanca Xicoy} and Bhatt, {Vijaya Raj} and Silverman, {Lewis R.} and Erba, {Harry P.} and Pierre Fenaux and Uwe Platzbecker and Valeria Santini and Wang, {Eunice S.} and Tallman, {Martin S.} and Stone, {Richard M.} and John Mascarenhas",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = aug,

doi = "10.1016/S2352-3026(20)30205-2",

language = "English (US)",

volume = "7",

pages = "e601--e612",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "8",

}

Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, R, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, A, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS, Stone, RM & Mascarenhas, J 2020, 'Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts', The Lancet Haematology, vol. 7, no. 8, pp. e601-e612. https://doi.org/10.1016/S2352-3026(20)30205-2

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. / Zeidan, Amer M.; Boddu, Prajwal C.; Patnaik, Mrinal M. et al.
In: The Lancet Haematology, Vol. 7, No. 8, 08.2020, p. e601-e612.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era

T2 - recommendations from a panel of international experts

AU - Zeidan, Amer M.

AU - Boddu, Prajwal C.

AU - Patnaik, Mrinal M.

AU - Bewersdorf, Jan Philipp

AU - Stahl, Maximilian

AU - Rampal, Raajit K.

AU - Shallis, Rory

AU - Steensma, David P.

AU - Savona, Michael R.

AU - Sekeres, Mikkael A.

AU - Roboz, Gail J.

AU - DeAngelo, Daniel J.

AU - Schuh, Andre C.

AU - Padron, Eric

AU - Zeidner, Joshua F.

AU - Walter, Roland B.

AU - Onida, Francesco

AU - Fathi, Amir

AU - DeZern, Amy

AU - Hobbs, Gabriela

AU - Stein, Eytan M.

AU - Vyas, Paresh

AU - Wei, Andrew H.

AU - Bowen, David T.

AU - Montesinos, Pau

AU - Griffiths, Elizabeth A.

AU - Verma, Amit K.

AU - Keyzner, Alla

AU - Bar-Natan, Michal

AU - Navada, Shyamala C.

AU - Kremyanskaya, Marina

AU - Goldberg, Aaron D.

AU - Al-Kali, Aref

AU - Heaney, Mark L.

AU - Nazha, Aziz

AU - Salman, Huda

AU - Luger, Selina

AU - Pratz, Keith W.

AU - Konig, Heiko

AU - Komrokji, Rami

AU - Deininger, Michael

AU - Cirici, Blanca Xicoy

AU - Bhatt, Vijaya Raj

AU - Silverman, Lewis R.

AU - Erba, Harry P.

AU - Fenaux, Pierre

AU - Platzbecker, Uwe

AU - Santini, Valeria

AU - Wang, Eunice S.

AU - Tallman, Martin S.

AU - Stone, Richard M.

AU - Mascarenhas, John

PY - 2020/8

Y1 - 2020/8

N2 - The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.

AB - The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.

UR - http://www.scopus.com/inward/record.url?scp=85087508878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087508878&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(20)30205-2

DO - 10.1016/S2352-3026(20)30205-2

M3 - Review article

C2 - 32563283

AN - SCOPUS:85087508878

SN - 2352-3026

VL - 7

SP - e601-e612

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 8

ER -

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this